Categories Cancer Treatment
Relevance: High
Most relevant for: People who receive chemotherapy for cancer treatment
Personal Story: Coping with chemotherapy-induced hair loss
Ovarian cancer survivor Stephanie Hess shared her personal story about how she coped with hair loss. This XRAY review also includes treatments to reduce this common side effect of chemotherapy. (9/28/20)
READ MORE ›.jpg)
Relevance: Medium-High
Most relevant for: People with metastatic triple-negative breast cancer
Guideline: FDA issues alert on a drug combination to treat triple-negative breast cancer
The immunotherapy drug Tecentriq (atezolizumab) is approved for use with Abraxane (nab-paclitaxel) to treat metastatic triple-negative breast cancer. Tecentriq is NOT approved for use with Taxol (paclitaxel). The Food and Drug Administration has issued an alert to doctors, researchers and patients warning that Tecentriq should not be used in combination with Taxol to treat patients with advanced triple-negative breast cancer. (09/18/20)
READ MORE ›
Relevance: High
Most relevant for: Women with advanced ovarian cancer whose tumor has a BRCA mutation or a type of tumor marker called homologous recombination deficiency (HRD)
Update: FDA approves the PARP inhibitor olaparib (Lynparza) in combination with bevacizumab (Avastin) as maintenance therapy for some women with advanced ovarian cancer
The FDA has approved the first drug combination to be used as a first-line maintenance therapy for some women with advanced ovarian cancer. (7/7/2020)
READ MORE ›
Relevance: Medium-High
Most relevant for: People with metastatic breast cancer with an inherited mutation in PALB2 or tumor with a BRCA mutation
Study: Promising research using a PARP inhibitor to treat metastatic breast cancer in people with an inherited PALB2 mutation or a tumor mutation in BRCA1 or BRCA2
Early results of a small study showed that women with metastatic breast cancer and an inherited mutation in PALB2 or an acquired tumor mutation in BRCA1 or BRCA2 benefitted from the PARP inhibitor olaparib (Lynparza). (6/18/20)
READ MORE ›
Relevance: High
Most relevant for: Men with metastatic castration-resistant prostate cancer who have certain inherited or tumor mutations in DNA repair genes
Update: PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) receive FDA approval for metastatic prostate cancer
The FDA approved two PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) for treatment of metastatic castration-resistant prostate cancer (mCRPC) in men who have certain inherited mutations or tumor mutations. (6/1/20)
READ MORE ›
Relevance: High
Most relevant for: People with advanced ovarian cancer who have had a complete or partial response to chemotherapy
Update: New FDA approval of PARP inhibitor for maintenance therapy in ovarian cancer
The FDA has approved the use of niraparib (Zejula) as a maintenance therapy for women with advanced ovarian cancer who have had a complete or partial response to chemotherapy. (5/7/20)
READ MORE ›
Relevance: High
Most relevant for: Patients with Her2-positive metastatic breast cancer
Update: FDA approves tucatinib (Tukysa) for metastatic Her2-positive breast cancer
The FDA has approved the use of tucatinib (Tukysa) in combination with chemotherapy as a treatment for people with metastatic Her2-positive breast cancer. This approval includes treatment of people whose breast cancer has spread to the brain. (4/29/20)
READ MORE ›
Relevance: High
Most relevant for: People with metastatic triple-negative breast cancer who have received at least two prior lines of treatment
Update: FDA approves new treatment for metastatic triple-negative breast cancer
The FDA approved the use of sacituzumab govitecan-hizy (Trodelvy), a treatment drug for people with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. (4/27/20)
READ MORE ›
Relevance: Medium
Most relevant for: People undergoing breast cancer treatment with chemotherapy
Study: Can taking dietary supplements during chemotherapy do more harm than good?
It's common for people to take dietary supplements after being diagnosed with cancer; however, they may reduce how well chemotherapy works. A new study suggests that some dietary supplements may cause more harm than benefit for breast cancer patients who are undergoing chemotherapy. (3/4/20)
READ MORE ›
Relevance: High
Most relevant for: Women with recurrent ovarian cancer
Study: Second surgery may not benefit women with recurrent ovarian cancer
Many women who have recurrent ovarian cancer have a second surgery. A new study suggests that women with platinum sensitive cancers who get chemotherapy alone may do as well as or better than women who have surgery followed by chemotherapy. (1/21/20)
READ MORE ›